Amylyx Pharmaceuticals (AMLX) Research & Development (2021 - 2026)

Amylyx Pharmaceuticals' Research & Development history runs 6 years deep, the most recent figure standing at $27.6 million for Q1 2026.

• In Q1 2026, Research & Development rose 24.82% year-over-year to $27.6 million; the TTM figure through Mar 2026 stood at $95.9 million (up 7.03% YoY), while the FY2025 annual figure was $90.4 million, down 13.14% from the prior year.
• Research & Development was $27.6 million for Q1 2026 at Amylyx Pharmaceuticals, up from $21.2 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $44.9 million in Q4 2023 to a low of $19.9 million in Q3 2025.
• Historically, Research & Development has averaged $26.1 million across 5 years, with a median of $24.2 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Research & Development surged 212.7% in 2022, then plunged 49.03% in 2024.
• A 5-year view of Research & Development shows it stood at $22.8 million in 2022, then soared by 96.88% to $44.9 million in 2023, then sank by 49.03% to $22.9 million in 2024, then decreased by 7.33% to $21.2 million in 2025, then surged by 30.16% to $27.6 million in 2026.
• The last three Research & Development figures came in at $27.6 million (Q1 2026), $21.2 million (Q4 2025), and $19.9 million (Q3 2025), per Business Quant data.